PBHNYSEPharmaceutical PreparationsFiscal year ends March 31
Prestige Consumer Healthcare Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$49.71−0.21 (-0.42%)
Close on Oct 19, 2026
- Market cap
- $2.37B
- P/E (TTM)
- 13.9
- Dividend yield
- –
Prestige Consumer Healthcare Inc. revenue by segment
By business segment
| Revenue | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North American OTC Healthcare | $226.21M | $234.55M | $235.70M | $230.76M | $212.58M | $248.95M | $238.93M | $239.81M | $232.32M | $231.13M | $236.57M | $244.42M | 85.1% | +6.4% |
| International OTC Healthcare | $39.50M | $47.07M | $47.75M | $43.36M | $36.95M | $47.57M | $51.38M | $43.97M | $34.83M | $45.86M | $46.18M | $41.89M | 14.9% | +6.9% |
By product or service
| Revenue | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | $260.34M | $278.66M | $283.05M | $273.76M | $249.28M | $296.20M | $290.00M | $283.55M | $266.84M | $276.73M | $282.72M | $286.31M | 98.0% | +4.4% |
| Gastrointestinal | $62.20M | $68.35M | $69.45M | $64.20M | $57.78M | $68.88M | $68.99M | $60.06M | $58.02M | $59.63M | $61.63M | $52.76M | 23.4% | +7.6% |
| Women's Health | $52.54M | $57.05M | $57.77M | $56.20M | $54.58M | $63.78M | $58.13M | $60.35M | $54.58M | $60.17M | $58.27M | $62.07M | 19.8% | -3.7% |
| Dermatologicals | $33.20M | $30.49M | $29.64M | $35.70M | $30.11M | $29.08M | $30.66M | $35.86M | $33.36M | $30.83M | $27.77M | $34.49M | 12.5% | +10.2% |
| Eye & Ear Care | $32.98M | $37.85M | $38.60M | $34.18M | $32.31M | $46.73M | $45.68M | $42.79M | $48.13M | $43.99M | $45.07M | $46.87M | 12.4% | +2.1% |
| Pain Relief | $26.80M | – | – | – | $28.93M | – | – | – | – | – | – | – | 10.1% | -7.4% |
| Oral Care | $22.36M | $28.00M | $26.58M | $24.77M | $21.70M | $27.09M | $23.08M | $24.08M | $20.77M | $25.31M | $23.46M | $22.78M | 8.4% | +3.0% |
| Cough, Cold & Allergy | $21.31M | – | – | – | $19.01M | – | – | – | – | – | – | – | 8.0% | +12.1% |
| Wellness, Sleep & Other | $14.33M | – | – | – | $5.11M | – | – | – | – | – | – | – | 5.4% | +180.5% |
| Other revenues | $5.38M | $2.96M | $399.00K | $355.00K | $252.00K | $322.00K | $315.00K | $237.00K | $307.00K | $266.00K | $26.00K | $9.00K | 2.0% | +2032.9% |
| Cough & Cold | – | $26.29M | $29.33M | $27.29M | $19.01M | $26.91M | $29.33M | $29.28M | $20.70M | $26.19M | $33.17M | $33.23M | – | – |
| Analgesics | – | $28.24M | $28.03M | $28.73M | $28.93M | $30.20M | $30.98M | $28.22M | $28.29M | $27.80M | $30.27M | $31.36M | – | – |
| Other OTC | – | $5.35M | $4.04M | $3.06M | $2.93M | $3.85M | $3.48M | $3.16M | $3.30M | $3.07M | $3.11M | $2.75M | – | – |
By region
From the segment and revenue-disaggregation notes of Prestige Consumer Healthcare's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.